Skip to main content

Table 2 Inhibitory effect of SB-203580 on hyperalgesia in the Hargraeves model

From: P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis

COMPOUND PAW WITHDRAWAL TIME PRE-DRUG TREATMENT (Seconds) PAW WITHDRAWAL TIME POST-DRUG TREATMENT (Seconds)
Vehicle 10.7 ± 0.6 8.0 ± 0.8
Indomethacin (10 mg/kg) 11.1 ± 0.6 14.5 ± 0.6*
SB-203580 (30 mg/kg) 10.8 ± 0.9 12.2 ± 1.2*
SB-203580 (10 mg/kg) 11.1 ± 0.6 11.8 ± 1.4*
SB-203580 (3 mg/kg) 12.0 ± 0.7 10.9 ± 1.2*
  1. The data are presented as the time for paw withdrawal from the heat source in seconds and are the mean ± S.E.M. from 10 rats per treatment group. The asterisk denotes a statistically significant difference (p < 0.05) between the vehicle and drug treatment groups.